Emergent BioSolutions Announces Completion of Acquisition of PaxVax for ~$270M
Shots:
- The acquisition is focus on development of vaccines for adenovirus types 4 and 7, and expanding the company’s vaccine product portfolio
- Emergent to pay an upfront ~$270M in cash to get hold of PaxVax’s two marketed vaccines- Vivotif and Vaxchora and pipeline products
- Vivotif (Typhoid Vaccine Live Oral Ty21a), and Vaxchora (Cholera Vaccine, Live, Oral) are novel vaccines approved by the US FDA for the prevention of typhoid fever and for prevention of cholera respectively
Click here to read full press release/ article | Ref: Emergent Biosolutions | Image: PaxVax
